Skip to main content
SpringerLink
Log in

Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage a changing from the current status?

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

We surveyed the comparative clinical features of patients with stage A1 and stage A2 prostate cancer. Preoperatively, prostate specific antigen (PSA) level was elevated in 50.0% of stage A2 patients as compared to 18.2% of stage A1 patients. Compared to low positivity of prostatic acid phosphatase in 12.5% of stage A2 and in 0% of stage A1, PSA was more sensitive to the presence of incidental carcinoma. During the observation period (mean 35.7 months) no stage A patient died of cancer. No evidence of the disease showed significantly higher rate, and death without cancer was significantly lower in stage A1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Correa, R., Anderson, R., Gibbons, R., Mason, T.: Latent carcinoma of the prostate: Why the controversy?J. Urol., 107, 450 (1973).

    Google Scholar 

  2. Jewett, H.: The present status of radical prostatectomy for stages A and B prostatic cancer.Urol. Clin. North Am., 2, 105 (1975).

    PubMed  CAS  Google Scholar 

  3. Cantrell, B. B., deKlerk, D. P., Eggleston, J. C., Boitnott, J. K., Walsh, P. C.: Pathologic factors that influence the prognosis of Stage A prostatic cancer—the influence of extent versus grade.J. Urol., 125, 516 (1981).

    PubMed  CAS  Google Scholar 

  4. Hermanek, P., Sobin, L. H.: UICC TNM Classification of Malignant Tumours. Springer-Verlag, Berlin 1987, p. 141.

    Google Scholar 

  5. Beahrs, G. H., Henson, D. E., Hutter, R. V. P., Meyers, M. H.: American Joint Committee on Cancer: Manual for Staging of Cancer. J. B. Lippincott, Philadelphia 1988.

    Google Scholar 

  6. Schroeder, F. H., Bloom, J. H., Hop, W. C., Mostofi, F. K.: The TNM classification of prostatic cancer.Prostate (Suppl.),4, 129 (1992).

    Google Scholar 

  7. Japanese Urological Association and The Japanese Pathological Society: General rule for clinical and pathological studies on prostatic cancer. 2nd ed. Kanehara 1992.

  8. Lorentz, K., Assel, K.: Studies on aryl phosphate hydrolysis by human acid phosphatase.Enzyme, 20, 248 (1975).

    PubMed  CAS  Google Scholar 

  9. Wang, M. C., Papsidero, L. D., Kuriyama, M., Valenzuela, L. A., Murphy, G. P., Chu, T. M.: Prostate antigen: A new potential marker for prostatic cancer.Prostate, 2, 89 (1981).

    PubMed  CAS  Google Scholar 

  10. Ogawa, Y., Morikawa, J., Ohsawa, R., Machida, T., Miki, M., Yanagisawa, M.: Purification and determination of human prostate specific antigen in serum.Radioisotopes, 33, 273 (1984).

    PubMed  CAS  Google Scholar 

  11. Emmett, J. L., Barber, K. W., Jackman, R. J.: Transrectal biopsy to detect prostate carcinoma: A review and report of 203 cases.J. Urol., 87, 460 (1962).

    PubMed  CAS  Google Scholar 

  12. Murphy, W. M., Dean, P. J., Brasfield, J. A., Tatum, L.: Incidental carcinoma of the prostate. How much sampling is adequate?Am. J. Surg. Pathol., 10, 170 (1986).

    Article  PubMed  CAS  Google Scholar 

  13. Thompson, I. M., Zeidman, E. J.: Current urological practice: Routine urological examination and early detection of carcinoma of the prostate.J. Urol., 148, 326 (1992).

    PubMed  CAS  Google Scholar 

  14. Haas, G. P., Montie, J. E., Pontes, J. E.: The state of prostate cancer screening in the United States.Eur. Urol., 23, 337 (1993).

    PubMed  CAS  Google Scholar 

  15. Ercole, C. J., Lange, P. H., Mathisen, M., Chiou, R. K., Reddy, P. K., Vessella, R. L.: Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.J. Urol., 138, 1181 (1987).

    PubMed  CAS  Google Scholar 

  16. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med., 317, 909 (1987).

    Article  PubMed  CAS  Google Scholar 

  17. Hudson, M. A., Bahnson, R. R., Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer.J. Urol., 142, 1011 (1989).

    PubMed  CAS  Google Scholar 

  18. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A., Cooner, W. H.: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer.J. Urol., 147, 815 (1992).

    PubMed  CAS  Google Scholar 

  19. Benson, M. C., Whang, I. S., Olsson, C. A., McMahon, D. J., Cooner, W. H.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen.J. Urol., 147, 817 (1992).

    PubMed  CAS  Google Scholar 

  20. Miller, J. S., Donovan, J. F., Williams, R. D.: Evaluation and treatment of stage A prostate cancer. In: Williams, R. D., Carroll, P. R. (eds): Urological Oncology. Pergamon Press, New York 1989, p. 113.

    Google Scholar 

  21. Blute, M. L., Zincke, H., Farrow, G. M.: Long-term followup of young patients with stage A adenocarcinoma of the prostate.J. Urol., 136, 840 (1986).

    PubMed  CAS  Google Scholar 

  22. McNeal, J. E., Bostwick, D. G., Kindorachuk, R. A., Redwine, E. A., Freiha, F. S., Stamey, T. A.: Patterns of progression in prostate cancer.Lancet, 11, 60 (1986).

    Article  Google Scholar 

  23. McNeal, J. E.: Origin and development of carcinoma in the prostate.Cancer, 23, 24 (1969).

    Article  PubMed  CAS  Google Scholar 

  24. McNeal, J. E.: Normal histology of the prostate.Am. J. Surg. Pathol., 12, 619 (1988).

    Article  PubMed  CAS  Google Scholar 

  25. McIntire, T. L., Murphy, W. M., Coon, J. S., Chandler, R. W., Schwartz, D., Conway, S., Weinstein, R. S.: The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland.Am. J. Clin. Pathol., 89, 370 (1988).

    PubMed  CAS  Google Scholar 

  26. Epstein, J. I., Paull, G., Eggleston, J. C., Walsh, P. C.: Prognosis of untreated stage A1 prostatic carcinoma: A study of 94 cases with extended followup.J. Urol., 136, 837 (1986).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, School of Medicine, Kanazawa University, Kanazawa, Japan

    K. Kunimi, T. Amano, S. -W. Lee, H. Fuse, T. Uchibayashi, K. Miyazaki & M. Ohkawa

Authors
  1. K. Kunimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. -W. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Fuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Uchibayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Ohkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kunimi, K., Amano, T., Lee, S.W. et al. Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage a changing from the current status?. International Urology and Nephrology 27, 575–585 (1995). https://doi.org/10.1007/BF02564744

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02564744

Keywords

Search

Navigation